NorthWest Biotherapeutics Inc (NWBO)

[Virgilio]

Financially, in my opinion, the explanation doesn't make sense. When you take into account conversion of warrants, you have to take into account money flows, which would in turn take into account no further dilution via stock offerings. This is not happening. Basing the model onto the warrant conversion add-on, simply doesn't make sense. The stock price didn't go up simply put because IMO that data was blended, 2017 old, and published in a journal which was not the one (or the range of the ones) expected. Moreover, at ASCO I do believe many people had the impression that the co. wanted to keep the lights on the trial without unblinding it soon, which mostly anyone is now expecting. Based on neutral expecations, without any partnership (which IMO would mean more dilution), any month longer the trial goes on, the lower prices are. This is all IMO, obviously.